Cargando…

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma

BACKGROUND: Drug-loaded nanoparticles have established their benefits in the fight against multiple myeloma; however, ligand-targeted nanomedicine has yet to successfully translate to the clinic due to insufficient efficacies reported in preclinical studies. METHODS: In this study, liposomal nanopar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omstead, David T., Mejia, Franklin, Sjoerdsma, Jenna, Kim, Baksun, Shin, Jaeho, Khan, Sabrina, Wu, Junmin, Kiziltepe, Tanyel, Littlepage, Laurie E., Bilgicer, Basar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607744/ https://www.ncbi.nlm.nih.gov/pubmed/33138841 http://dx.doi.org/10.1186/s13045-020-00965-4

Ejemplares similares

Determination of Crucial Immunogenic Epitopes in Major Peanut Allergy Protein, Ara h2, via Novel Nanoallergen Platform
por: Deak, Peter E., et al.
Publicado: (2017)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells
por: Nakayama, Shoko, et al.
Publicado: (2012)

Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
por: Cengiz, Arzu, et al.
Publicado: (2018)

Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma()
por: Krishnan, Sabna Rajeev, et al.
Publicado: (2016)

Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma
por: Choudhuri, Jui, et al.
Publicado: (2023)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

Human CD38(hi)CD138(+) Plasma Cells Can Be Generated In Vitro from CD40-Activated Switched-Memory B Lymphocytes
por: Itoua Maïga, Rayelle, et al.
Publicado: (2014)

The Anti-CD38 Antibody Therapy in Multiple Myeloma
por: Petrucci, Maria Teresa, et al.
Publicado: (2019)

CD38-Directed Therapies for Management of Multiple Myeloma
por: Hashmi, Hamza, et al.
Publicado: (2021)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
por: Soloveva, Maiia, et al.
Publicado: (2023)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study
por: Dass, Jasmita, et al.
Publicado: (2019)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
por: Zannetti, Beatrice Anna, et al.
Publicado: (2020)

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
por: Lee, Je-Jung
Publicado: (2010)

Syndecan-1 (CD138), Carcinomas and EMT
por: Couchman, John R.
Publicado: (2021)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
por: Saltarella, Ilaria, et al.
Publicado: (2020)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38‐Targeted Lipid Nanoparticles
por: Tarab‐Ravski, Dana, et al.
Publicado: (2023)

Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout
por: Jacak, Jaroslaw, et al.
Publicado: (2013)

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
por: KAWANO, YAWARA, et al.
Publicado: (2012)

Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells
por: KAWANO, YAWARA, et al.
Publicado: (2013)

Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells
por: Kishimoto, Renata Kiyomi, et al.
Publicado: (2016)

Comment on: “Validation of interphase fluorescence in situ hybridization (iFISH) of CD138 positive cells in multiple myeloma”()
por: Zalcberg Renault, Ilana
Publicado: (2016)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
por: van de Donk, Niels W.C.J., et al.
Publicado: (2018)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
por: Bae, Jooeun, et al.
Publicado: (2014)

Comparison of the IHC Markers CD138 and CD43 in Oral Leukoplakia: An Original Research
por: Akkaloori, Anitha, et al.
Publicado: (2023)

Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo
por: Kiziltepe, T, et al.
Publicado: (2012)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
por: Qasaimeh, Mohammad A., et al.
Publicado: (2017)

Paclitaxel-Fe(3)O(4) nanoparticles inhibit growth of CD138(−) CD34(−) tumor stem-like cells in multiple myeloma-bearing mice
por: Yang, Cuiping, et al.
Publicado: (2013)

Amyloid arthropathy associated with multiple myeloma: polyarthritis without synovial infiltration of CD20+ or CD38+ cells
por: Pessler, Frank, et al.
Publicado: (2014)

P1355: DELIVERY OF THERAPEUTIC RNA TO THE BONE MARROW IN MULTIPLE MYELOMA USING CD38-TARGETED LIPID NANOPARTICLES
por: Tarab-Ravski, Dana, et al.
Publicado: (2023)

Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma
por: Bartosińska, Joanna, et al.
Publicado: (2021)

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o7b8svm0e3gn7s8jda1978gsqc